Israel - English - Ministry of Health

teva israel ltd - lansoprazole - capsules - lansoprazole 30 mg - lansoprazole - lansoprazole - • treatment of duodenal and gastric ulcer • treatment of reflux oesophagitis• prophylaxis of reflux oesophagitis• eradication of helicobacter pylori (h. pylori) concurrently given with appropriate antibiotic therapy for treatment of h.pylori-associated ulcers• treatment of nsaid-associated benign gastric and duodenal ulcers in patients requiring continued nsaid treatment• prophylaxis of nsaid-associated gastric ulcers and duodenal ulcers in patients at risk requiring continued therapy• symptomatic gastroesophageal reflux disease• zollinger-ellison syndrome.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole 15 mg - lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see clinical studies (14.1)] . triple therapy: lansoprazole delayed-release capsules/amoxicillin/clarithromycin lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate h. pylori . eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14.2)] . please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole delayed-release capsules/amoxicillin lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in adults for the treatment of patients with h. pylori infection and duodenal ulcer disease (

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 40 mg - pantoprazole sodium delayed-release tablets are indicated for: pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. pantoprazole sodium delayed-release tablets are contra

United States - English - NLM (National Library of Medicine)

rxchange co. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - pantoprazole sodium delayed-release tablets usp are indicated for: pantoprazole sodium delayed-release tablets usp are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets usp may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium delayed-release tablets usp are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium delayed-release tablets usp are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. pantoprazole sodium delayed-release tablets are contraindicated in patients with know

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 40 mg - omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. triple therapy omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. dual therapy omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in patients who fail therapy, susceptibil

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole tablets are indicated for the treatment of: - schizophrenia [see clinical studies (14.1) ] additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2) ]. pregnancy category c pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs (including aripiprazole) during t

Israel - English - Ministry of Health

inovamed ltd - esomeprazole as magnesium trihydrate - gastro resistant tablets - esomeprazole as magnesium trihydrate 20 mg - esomeprazole - esomeprazole inovamed tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.esomeprazole inovamed 20 mg tablets are indicated in adolescents from the age of 12 years forgastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophgeal reflux disease (gerd)in combination with antibiotics in treatment of duodenal ulcer caused by helicobactor pylori

Israel - English - Ministry of Health

inovamed ltd - esomeprazole as magnesium trihydrate - gastro resistant tablets - esomeprazole as magnesium trihydrate 40 mg - esomeprazole - esomeprazole inovamed tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.esomeprazole inovamed 40 mg tablets are indicated in adolescents from the age of 12 years for;gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis

Israel - English - Ministry of Health

dexcel ltd, israel - omeprazole - caplets - omeprazole 20 mg - omeprazole - omeprazole - relief of reflux-like symptoms (e.g. heartburn) with frequency of two or more days a week in sufferers aged 18 and over.

Israel - English - Ministry of Health

dexcel ltd, israel - lorazepam - tablets - lorazepam 1 mg - lorazepam - lorazepam - anxiety and tension.